Literature DB >> 17364157

[Immunization in children and adolescents with rheumatic diseases].

K Minden1, M Niewerth, M Borte, W Singendonk, J-P Haas.   

Abstract

Vaccinations represent a special problem in children and adolescents with inflammatory rheumatic diseases. There are very limited data on the safety and efficacy of vaccines in these patients, and guidelines for immunization are missing. The immunosuppressive therapy often necessary for these patients gives rise to additional uncertainty. In addition, many colleagues consider vaccination to increase the risk of relapse of the rheumatic illness. As a consequence, there are substantial variations in practicing vaccination in these patients, resulting in insufficient vaccination coverage rates. For example, every third patient with juvenile idiopathic arthritis is incompletely vaccinated; this even includes toxoid vaccines for tetanus and diphtheria. The benefit of vaccinations, which far outweighs their potential risks, is well recognized even in patients with autoimmune diseases. These patients in particular require a special protection from infections due to their immunosuppressive therapies. Therefore, children and adolescents with rheumatic diseases should be immunized according to the Standing Immunization Commission of the Robert Koch Institute recommendations whenever possible. However, the time of vaccination must be carefully selected, taking disease activity and treatment into account.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17364157     DOI: 10.1007/s00393-007-0150-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  40 in total

1.  Vaccines for transplant recipients.

Authors:  D C Molrine; P L Hibberd
Journal:  Infect Dis Clin North Am       Date:  2001-03       Impact factor: 5.982

2.  Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.

Authors:  M C Kapetanovic; T Saxne; J-A Nilsson; P Geborek
Journal:  Rheumatology (Oxford)       Date:  2006-11-18       Impact factor: 7.580

3.  Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004.

Authors:  Tetsuo Nakayama; Kazumasa Onoda
Journal:  Vaccine       Date:  2006-08-04       Impact factor: 3.641

4.  [Not Available].

Authors:  A Dippelhofer; C Meyer; P Kamtsiuris; G Rasch; S Reiter; K E Bergmann
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2002-04       Impact factor: 1.513

Review 5.  Juvenile idiopathic arthritis.

Authors:  Andrea T Borchers; Carlo Selmi; Gurtej Cheema; Carl L Keen; Yehuda Shoenfeld; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2005-10-27       Impact factor: 9.754

Review 6.  A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review.

Authors:  M R Geier; D A Geier
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

7.  Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation.

Authors:  A J Tingle; M Allen; R E Petty; G D Kettyls; J K Chantler
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

8.  Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and a review of the evidence.

Authors:  K Davies; P Woo
Journal:  Rheumatology (Oxford)       Date:  2002-08       Impact factor: 7.580

9.  A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database.

Authors:  D A Geier; M R Geier
Journal:  Clin Exp Rheumatol       Date:  2002 Nov-Dec       Impact factor: 4.473

10.  Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis.

Authors:  Ori Elkayam
Journal:  Clin Dev Immunol       Date:  2006 Jun-Dec
View more
  7 in total

1.  Vaccination safety update.

Authors:  Burkhard Schneeweiss; Michael Pfleiderer; Brigitte Keller-Stanislawski
Journal:  Dtsch Arztebl Int       Date:  2008-08-25       Impact factor: 5.594

Review 2.  Immunization of children with secondary immunodeficiency.

Authors:  Susanna Esposito; Elisabetta Prada; Mara Lelii; Luca Castellazzi
Journal:  Hum Vaccin Immunother       Date:  2015-07-15       Impact factor: 3.452

3.  [Practical problems by implementation of vaccination recommendations].

Authors:  C Fendler; E Saracbasi; F Dybowski; F Heldmann; J Braun
Journal:  Z Rheumatol       Date:  2012-02       Impact factor: 1.372

4.  Vaccination coverage in immunosuppressed patients: results of a regional health services research study.

Authors:  Niels Teich; Tobias Klugmann; Astrid Tiedemann; Babett Holler; Joachim Mössner; Anke Liebetrau; Ingolf Schiefke
Journal:  Dtsch Arztebl Int       Date:  2011-02-18       Impact factor: 5.594

5.  [Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2].

Authors:  F Speth; N Wellinghausen; J-P Haas
Journal:  Z Rheumatol       Date:  2013-11       Impact factor: 1.372

6.  Vaccination completeness in children with rheumatic diseases: A longitudinal, observational multicenter cohort study in Switzerland.

Authors:  Tatjana Welzel; Jasmin Kuemmerle-Deschner; Constantin Sluka; Raffaella Carlomagno; Elvira Cannizzaro Schneider; Daniela Kaiser; Michael Hofer; Veronique Hentgen; Andreas Woerner
Journal:  Front Pediatr       Date:  2022-09-08       Impact factor: 3.569

7.  The vaccine coverage and vaccine immunity status and risk factors of non-protective levels of antibodies against vaccines in children with juvenile idiopathic arthritis: cross-sectional Russian tertiary Centre study.

Authors:  Mikhail M Kostik; Natalia A Lubimova; Irina V Fridman; Olga V Goleva; Susanna M Kharit
Journal:  Pediatr Rheumatol Online J       Date:  2021-07-05       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.